{"disease":{"id":"advanced-breast-cancer-female","name":"advanced breast cancer female"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05439499","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":434,"lead_sponsor_name":"Ahon Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05438810","title":"This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":312,"lead_sponsor_name":"Ahon Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07038369","title":"A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":134,"lead_sponsor_name":"Atavistik Bio, Inc","has_results":false},{"nct_id":"NCT02600923","title":"Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05092373","title":"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05812326","title":"PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02142868","title":"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Pfizer","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}